These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2442535)

  • 1. Dihydroergotamine: pharmacokinetics, pharmacodynamics, and mechanism of venoconstrictor action in beagle dogs.
    Müller-Schweinitzer E; Rosenthaler J
    J Cardiovasc Pharmacol; 1987 Jun; 9(6):686-93. PubMed ID: 2442535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics and pharmacokinetics of dihydroergotamine (DHE) in conscious beagle dogs.
    Müller-Schweinitzer E
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):162-5. PubMed ID: 2459013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Experimental pharmacological studies of the venous tonus-modifying effect of dihydroergotamine].
    Glusa E
    Z Gesamte Inn Med; 1984 Sep; 39(17):414-7. PubMed ID: 6095548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venoconstrictor responses to dihydroergocristine and dihydroergotamine: evidence for the involvement of 5-HT1 like receptors.
    Müller-Schweinitzer E
    Cardiovasc Drugs Ther; 1990 Dec; 4(6):1455-60. PubMed ID: 2127899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ex vivo studies after oral treatment of the beagle with dihydroergotamine.
    Müller-Schweinitzer E; Rosenthaler J
    Eur J Pharmacol; 1983 Apr; 89(1-2):1-8. PubMed ID: 6861880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha-adrenoceptors, 5-hydroxytryptamine receptors and the action of dihydroergotamine in human venous preparations obtained during saphenectomy procedures for varicose veins.
    Müller-Schweinitzer E
    Naunyn Schmiedebergs Arch Pharmacol; 1984 Oct; 327(4):299-303. PubMed ID: 6096723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions of dihydroergotamine with etilefrine in human leg veins in vitro and in situ.
    Barthel W; Glusa E; Koth W
    Int J Clin Pharmacol Ther Toxicol; 1987 Feb; 25(2):63-9. PubMed ID: 2881898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological actions of the main metabolites of dihydroergotamine.
    Müller-Schweinitzer E
    Eur J Clin Pharmacol; 1984; 26(6):699-705. PubMed ID: 6489409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the pharmacology of venous smooth muscle from dog and man.
    Müller-Schweinitzer E
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1979; 106(5-6):690-704. PubMed ID: 94863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Venous tonus-modifying effect, pharmacokinetics and undesired effects of dihydroergotamine].
    Barthel W
    Z Gesamte Inn Med; 1984 Sep; 39(17):417-28. PubMed ID: 6390997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pizotifen, an antimigraine drug with venoconstrictor activity in vivo.
    Müller-Schweinitzer E
    J Cardiovasc Pharmacol; 1986; 8(4):805-10. PubMed ID: 2427822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies on 5-hydroxytryptamine receptors on isolated human femoral veins and arteries and the influence of dihydroergotamine.
    Glusa E; Markwardt F
    Pharmacology; 1984; 29(6):336-42. PubMed ID: 6505006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between the venoconstrictor activity of dihydroergotamine and its pharmacokinetics during acute and chronic oral dosing.
    de Marées H; Welzel D; de Marées A; Klotz U; Tiedjen KU; Knaup G
    Eur J Clin Pharmacol; 1986; 30(6):685-9. PubMed ID: 3533566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo pharmacodynamic interactions between two drugs used in orthostatic hypotension--midodrine and dihydroergotamine.
    Jourdan G; Verwaerde P; Pathak A; Tran MA; Montastruc JL; Senard JM
    Fundam Clin Pharmacol; 2007 Feb; 21(1):45-53. PubMed ID: 17227444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is known about the action of dihydroergotamine on the vasculature in man?
    Müller-Schweinitzer E
    Int J Clin Pharmacol Ther Toxicol; 1984 Dec; 22(12):677-82. PubMed ID: 6396240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venoconstrictor effects of dihydroergotamine after intranasal and intramuscular administration.
    Aellig WH; Rosenthaler J
    Eur J Clin Pharmacol; 1986; 30(5):581-4. PubMed ID: 3758146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct effects of vasoactive substances on superficial human veins in vivo.
    Aellig WH
    Int Angiol; 1985; 4(2):235-42. PubMed ID: 3913713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological profile of the inhibition by dihydroergotamine and methysergide on the cardioaccelerator sympathetic outflow in pithed rats.
    Lozano-Cuenca J; Muñoz-Islas E; González-Hernández A; Centurión D; Cobos-Puc LE; Sánchez-López A; Pertz HH; Villalón CM
    Eur J Pharmacol; 2009 Jun; 612(1-3):80-6. PubMed ID: 19356724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The recording of venous compliance in the conscious dog: a method for the assessment of venoconstrictor agents.
    Müller-Schweinitzer E
    J Pharmacol Methods; 1984 Aug; 12(1):53-8. PubMed ID: 6536814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro studies on the duration of action of dihydroergotamine.
    Müller-Schweinitzer E
    Int J Clin Pharmacol Ther Toxicol; 1980; 18(2):88-91. PubMed ID: 7372380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.